skip to main content
Show Results with:

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Salles, G. et al.

The lancet. VOL 377; NUMBER 9759, ; 2011, 42-51 -- Elsevier Science B.V., Amsterdam. -- 2011

Online access

Notes here allow you and other users to comment and make notes on items, viewable by the whole community.
NB: Please use the Report Catalogue Error form to advise us of catalogue inaccuracies.

Log in to add a note

Tags allow you and others to define and search on related groups of items.

Log in to add / remove tags

Searching Remote Databases, Please Wait